BetterLife Pharma Appoints LifeSci Advisors as Investor Relations Firm
LifeSci will receive monthly cash fees and no equity compensation under an initially 12-month engagement.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BetterLife Pharma (BETRF) has retained LifeSci Advisors to support investor relations and corporate communications as it prepares for clinical development. The engagement carries monthly fees of USD$24,250 for investor relations and USD$2,500 for media programs, with no equity-based compensation. Its initial 12-month term renews automatically for successive 12-month periods unless either party provides 60 days' prior written notice.
BetterLife targets an Investigational New Drug application in the first quarter of 2027 for BETR-001 and plans to initiate clinical development during 2027. The drug is being developed as a potential preventive treatment for chronic migraine and cluster headache. The company recently completed a USD$100 million financing led by Deep Track Capital and appointed headache experts Peter Goadsby and Richard Lipton as Scientific Advisory Board co-chairs.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointUSD$100 million financing led by Deep Track Capital recently strengthened BetterLife's balance sheet. 96% of market cap
- Moderate point. Forward-looking: it has not happened yet and may not happen.BETR-001 development plans target an IND application in first-quarter 2027 and clinical development during 2027.
- Minor pointNo equity-based compensation will be paid to LifeSci under the engagement.
Negative
- Minor pointMonthly fees of USD$24,250 cover investor relations, with another USD$2,500 for media programs.
- Minor pointInitial 12-month commitment automatically renews for successive 12-month periods unless either party gives 60 days' prior written notice.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Engagement to support expanded investor outreach as BetterLife advances BETR-001 toward planned clinical development in 2027
Vancouver, British Columbia--(Newsfile Corp. - October 27, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), a biotechnology company developing BETR-001 for chronic cluster headache and chronic migraine, today announced that it has retained LifeSci Advisors ("LifeSci" or "LifeSci Advisors") to support its investor relations and corporate communications activities. The engagement of LifeSci is being completed pursuant to the policies of the Canadian Securities Exchange (the "CSE").
The appointment comes as BetterLife advances BETR-001, a novel, non-hallucinogenic neuroplastogen being developed as a potential preventive treatment for chronic migraine and cluster headache. The Company is targeting submission of an Investigational New Drug (IND) application in the first quarter of 2027, with plans to initiate clinical development during the year. BetterLife has also recently strengthened its Scientific Advisory Board with the appointments of internationally recognized headache experts, Professors Peter Goadsby and Richard Lipton, as Co-Chairs. In addition, the Company recently fortified its balance sheet through a USD
Pursuant to the terms of the engagement, LifeSci Advisors will be paid monthly fees of USD
"We are seeing strong interest from the investment community as we advance BETR-001 toward the clinic and prepare for important development milestones in 2027," said Ahmad Doroudian, PhD, Chief Executive Officer of BetterLife. "As such, we believe this is the right time to enhance our investor relations efforts and broaden awareness of BETR-001's differentiated profile and therapeutic potential. LifeSci's understanding of the biotechnology sector and its established relationships in the investment community will be valuable as we communicate our progress and execute on our development strategy."
LifeSci Advisors is a premier investor relations and strategic advisory firm dedicated exclusively to the life sciences industry. The firm partners with public and private biotechnology, pharmaceutical, medical device and diagnostics companies to execute investor relations programs and deepen engagement with the investment community. LifeSci Advisors is located at 1700 Broadway, 40th floor, New York, NY, 10019, USA. It acts at arms-length to the Company and currently holds no common shares or other securities of the Company.
About BETR-001
BETR-001 is a non-hallucinogenic derivative of 2-bromo-lysergic acid diethylamide (2-Br-LSD) in development for the preventive treatment of chronic cluster headache and chronic migraine. The Company holds a granted U.S. composition-of-matter patent covering BETR-001. BETR-001 is an investigational product and has not been approved by any regulatory authority.
The Company makes no medical, treatment or health benefit claims about the Company's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding BETR-001 or other programs of the Company. The efficacy of such products has not been confirmed by approved research. There is no assurance that BETR-001 or other programs of the Company can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company's performance and operations.
About BetterLife Pharma Inc.
BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing BETR-001 to treat various neurological disorders, such as chronic cluster headache and chronic migraine.
For further information, please visit BetterLife Pharma.
Contact
Ahmad Doroudian, Chief Executive Officer
Email: Ahmad.Doroudian@blifepharma.com
Phone: 1-604-221-0595
Brian Ritchie (at LifeSci Advisors)
Email: britchie@lifesciadvisors.com
Phone 1-646-656-1564
Cautionary Note Regarding Forward-Looking Information
Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, "forward-looking statements") and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as "may", "should", "could", "potential", "possible", "intend", "estimate", "plan", "anticipate", "expect", "believe" or "continue", or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the investor relations and corporate communication activities to be conducted by LifeSci; the expected timing of the Company's submission of an Investigational New Drug (IND) application and initiation of clinical development of BETR-001, and the Company's ability to seek strategic alternatives for further development of its drug candidate for treatment of viral infections.
Any forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the markets for the treatment of neurological disorders and viral infections; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in the Company's annual information form for the year ended January 31, 2026, which are available under the Company's profile on SEDAR+ at www.sedarplus.ca and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov/edgar. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
The CSE has not approved or disapproved the contents of this news release and is not responsible for the adequacy and accuracy of the contents herein.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/321060
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What will BetterLife Pharma pay LifeSci Advisors for investor relations?
BetterLife will pay LifeSci USD$24,250 monthly for investor relations and USD$2,500 monthly for media programs. LifeSci will receive no equity-based compensation. The initial engagement lasts 12 months and automatically renews for successive 12-month periods unless either party provides 60 days' prior written notice.
When does BetterLife Pharma plan to advance BETR-001 into clinical development?
BetterLife targets submission of an Investigational New Drug application in the first quarter of 2027 and plans to initiate clinical development during 2027. BETR-001 is being developed as a potential preventive treatment for chronic migraine and cluster headache.